statistiche ricercatore

Continente	#
NA - Nord America	382
AS - Asia	310
EU - Europa	207
SA - Sud America	42
AF - Africa	14
Continente sconosciuto - Info sul continente non disponibili	13
Totale	968

Nazione	#
US - Stati Uniti d'America	371
SG - Singapore	123
CN - Cina	74
IT - Italia	49
DE - Germania	39
BR - Brasile	33
VN - Vietnam	28
FR - Francia	25
GB - Regno Unito	21
IN - India	21
IE - Irlanda	16
JP - Giappone	13
SE - Svezia	12
FI - Finlandia	11
KR - Corea	9
ID - Indonesia	8
BD - Bangladesh	7
NL - Olanda	7
ZA - Sudafrica	7
AR - Argentina	6
HK - Hong Kong	6
RU - Federazione Russa	5
AT - Austria	4
CA - Canada	4
IQ - Iraq	4
ES - Italia	3
MA - Marocco	3
MX - Messico	3
PL - Polonia	3
SA - Arabia Saudita	3
AW - Aruba	2
CH - Svizzera	2
HU - Ungheria	2
IL - Israele	2
LT - Lituania	2
MK - Macedonia	2
PK - Pakistan	2
TR - Turchia	2
A2 - ???statistics.table.value.countryCode.A2???	1
AO - Angola	1
BG - Bulgaria	1
BS - Bahamas	1
CO - Colombia	1
DZ - Algeria	1
EC - Ecuador	1
ET - Etiopia	1
GE - Georgia	1
HN - Honduras	1
JO - Giordania	1
KE - Kenya	1
KZ - Kazakistan	1
LK - Sri Lanka	1
OM - Oman	1
PS - Palestinian Territory	1
RO - Romania	1
SI - Slovenia	1
TW - Taiwan	1
UA - Ucraina	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	956

Nome	#
Advanced and recurrent endometrial cancer: State of the art and future perspectives	146
Recent progress in the use of pharmacotherapy for endometrial cancer	124
Immunotherapy-related imaging findings in patients with gynecological malignancies: What radiologists need to know	117
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?	116
Laparoscopic versus robotic hysterectomy in obese and extremely obese patients with endometrial cancer: A multi-institutional analysis	104
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	103
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives	96
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	81
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	81
Totale	968

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	13	0	0	0	1	0	0	0	4	0	1	3	4
2022/2023	74	6	6	1	7	2	7	2	1	11	7	18	6
2023/2024	117	2	22	14	11	6	15	16	1	4	3	13	10
2024/2025	221	6	1	23	3	13	9	13	2	19	39	49	44
2025/2026	458	58	16	29	59	75	37	71	28	37	29	8	11
2026/2027	72	47	15	10	0	0	0	0	0	0	0	0	0
Totale													968

IRIS UniCatt